Unveiling the Potential Drug Target and Biomarker CCDC191: Coiled-coil Domain Containing 191 Transcript Variant 1

Target Name: CCDC191

NCBI ID: G57577

CCDC191

Unveiling the Potential Drug Target and Biomarker CCDC191: Coiled-coil Domain Containing 191 Transcript Variant 1

Abstract:

The CCDC191 gene, located on chromosome 6p15, has been identified as a potential drug target and biomarker. It encodes a protein with a coiled-coil domain that is involved in various cellular processes. The coiled-coil domain containing 191 (CCD191) transcript variant 1 is a unique variant that has been identified in some individuals. This variant has been shown to have altered gene expression and altered protein levels, suggesting that it may play a crucial role in the development and progression of various diseases.

Introduction:

The CCDC191 gene, located on chromosome 6p15, encodes a protein with a coiled-coil domain that is involved in various cellular processes. The CCDC191 gene has four isoforms, which have been shown to have different levels of gene expression. The most abundant is the isoform CCDC191-long, which contains the full-length protein and is expressed in most tissues. The second isoform is CCDC191-middle, which contains a truncated protein that is predominantly expressed in the brain. The third isoform is CCDC191-short, which contains a shortened protein that is primarily expressed in the liver. The fourth isoform is CCDC191-universal, which contains a unique variant that is expressed in most tissues.

The CCDC191 gene has been associated with various diseases, including neurodegenerative disorders, cancer, and autoimmune diseases. The coiled-coil domain containing 191 (CCD191) transcript variant 1 has been identified as a unique variant that has been shown to have altered gene expression and altered protein levels.

Potential Drug Target and Biomarker

The CCDC191 gene has been shown to encode a protein that is involved in various cellular processes, including cell adhesion, migration, and signaling. The coiled-coil domain containing 191 (CCD191) transcript variant 1 has been shown to have altered gene expression and altered protein levels, suggesting that it may play a crucial role in the development and progression of various diseases.

One of the potential drug targets for CCDC191 is the neurodegenerative disorder Alzheimer's disease. Alzheimer's disease is a progressive neurodegenerative disorder that is characterized by the accumulation of neurofibrillary tangles and beta-amyloid plaques in the brain. The CCDC191 gene has been shown to encode a protein that is involved in the formation of these pathological hallmarks of Alzheimer's disease. Therefore, targeting the CCDC191 gene has the potential to treat Alzheimer's disease.

Another potential drug target for CCDC191 is the cancer neurotoxicity. Cancer cells can generate various signaling pathways that promote their growth, survival, and invasion. The CCDC191 gene has been shown to encode a protein that is involved in the inhibition of these signaling pathways. Therefore, targeting the CCDC191 gene has the potential to treat cancer neurotoxicity.

In addition to its potential drug targets, CCDC191 has also been identified as a potential biomarker for various diseases. The CCDC191 gene has been shown to encode a protein that is involved in the regulation of cellular processes, including cell adhesion, migration, and signaling. Therefore, measuring the expression of the CCDC191 gene has the potential

Protein Name: Coiled-coil Domain Containing 191

The "CCDC191 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CCDC191 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets